Colitis, Ulcerative Clinical Trial
— APPEAROfficial title:
A Multicentre Trial of the Anterior Perineal PlanE for Ultra Low Anterior Resection of the Rectum (The APPEAR Technique) in the Prevention of Permanent Stoma in Benign and Malignant Disease
Verified date | June 2008 |
Source | Queen Mary University of London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Anal sphincter preserving operations are now commonplace for both cancer and non-cancerous rectal diseases. However, this has not always been the case and this development has been facilitated by the invention of circular stapling instruments, which allow the bowel to be reconnected to the anal sphincters, where it would almost be impossible to do so manually. Nevertheless, some patients still require a permanent ostomy, as even with stapling devices ultra low joins of the bowel and sphincter muscles cannot always be performed by a conventional surgery. Therefore, a variety of alternative techniques have been proposed to avoid a permanent ostomy, but these have not become widespread due to the technical difficulty in performing them, their failure to completely eradicate rectal disease, and the damage they inflict upon the anal sphincters resulting in poor bowel function after surgery. The ideal ultra low sphincter preserving operation should remove the rectal disease entirely, allow the small or large bowel to be safely joined to the anal sphincters under direct vision, and retain the sphincter mechanism in its entirety. We propose such a technique that we term the APPEAR procedure, which approaches the lower third of the rectum via an incision between the scrotum or vagina, and the anal sphincters. This procedure preserves sphincter integrity, and allows either a stapled or manual join of the bowel to the sphincter mechanism, under direct vision. This trial is being conducted as a pilot study, with the procedure only offered to patients for whom a conventional sphincter saving procedure was technically impossible, or contraindicated.
Status | Completed |
Enrollment | 23 |
Est. completion date | November 1, 2015 |
Est. primary completion date | August 1, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: - All patients regardless of sex - Undergoing surgery (with curative intent) to excise the lower third of the rectum who may require a permanent stoma - Deemed suitable by multidisciplinary team. Exclusion Criteria: - Patients under the age of 16 - Patients in whom sphincter preservation has already been deemed inappropriate for medical or surgical reasons (e.g. by an MDT for oncological cure), or in whom surgery has been deemed generally inappropriate. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Centre For Academic Surgery, The Royal London Hospital | London | England |
Lead Sponsor | Collaborator |
---|---|
Queen Mary University of London |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Yield (within each arm of study) | 5 years | ||
Primary | Functional assessment (faecal continence) | 5 years | ||
Primary | Surgical Safety Assessment | 1 year | ||
Primary | Oncological safety assessment - where appropriate | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
Completed |
NCT03494764 -
Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares
|
Phase 2 | |
Recruiting |
NCT03937609 -
TITRATE (inducTIon for acuTe ulceRATivE Colitis)
|
Phase 4 | |
Completed |
NCT00503243 -
Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03606499 -
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
|
||
Completed |
NCT02537210 -
Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis
|
N/A | |
Active, not recruiting |
NCT02316678 -
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
|
N/A | |
Completed |
NCT00488631 -
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT00928681 -
A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis
|
Phase 1 | |
Recruiting |
NCT05242484 -
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT01036022 -
Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis
|
Phase 2 | |
Recruiting |
NCT03841045 -
Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases
|
||
Active, not recruiting |
NCT05528510 -
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT02825914 -
CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)
|
N/A | |
Recruiting |
NCT06049017 -
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT04567628 -
Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes
|
||
Withdrawn |
NCT05999708 -
A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT05611671 -
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
|
Phase 2 | |
Active, not recruiting |
NCT03596645 -
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03648541 -
BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
|
Phase 2 |